#FATE THERAPEUTICS STOCK UPDATE#

In return, Fate got a $10M upfront payment with 50/50 cost sharing to the pre-IND stage. In addition, Fate has the 50/50 option in both the United States and Europe. Similar to the Janssen collaboration, Fate will be responsible for preclinical development and Ono has worldwide development and commercialization rights. Ono will provide proprietary antigen binding domains to develop CAR-targeted therapies by integrating numerous mechanisms of action to be operative in the solid tumor microenvironment.

In addition, Janssen flips the bill for all development costs.įate's second collaboration is with ONO Pharmaceutical for off-the-shelf CAR NK-cell and CAR T-cell therapies for the treatment of solid tumors. Fate is also eligible for over $3B in milestones, as well as double-digit royalties. In terms of the financials, Fate has a $100M upfront along with $50M in equity for Janssen. Janssen has options for worldwide development and commercialization, but Fate has the right to a 50/50 agreement in the United States.

According to the agreement, Fate is responsible for preclinical development up to IND submission.

Moreover, these cell therapies are projected to be more cost-effective compared to other cell I-O therapies and will target both liquid and solid tumors.įate Therapeutics iPSC Platform Overview (Fate Therapeutics)įate's iPSC platform has over 300 issued patents and 150 pending patent applications that are owned or licensed by the company.įate has a couple of impressive collaborations with leading oncology outfits including one with Janssen Pharmaceuticals of Johnson & Johnson ( JNJ) for off-the-shelf CAR NK cell and CAR T-cell therapies for hematological malignancies and solid tumors. These iPSC lines are genetically engineered and indefinitely expanded in culture to be refined into off-the-shelf NK cell, T cell, and CD34+ treatments. Fate uses human induced pluripotent stem cells 'iPSCs' spawned from their iPSC platform to generate clonal master iPSC lines, which are essentially blank canvas cells that are a renewable source with uniform properties. In addition, I discuss my updated strategy and how I plan on managing a FATE 2.0 position in the coming quarters.įate Therapeutics Logo (Fate Therapeutics) Background on Fate Therapeuticsįate Therapeutics is a clinical-stage biotech developing first-in-class cell immunotherapies for the treatment of cancer. I intend to provide a brief background on Fate Therapeutics and the company's progress thus far. This time, I plan on sticking to my updated speculative strategy and will enjoy having a 'house money' FATE position in my 'Bio Boom' portfolio. Now, I am looking to return to Fate Therapeutics with my new strategy to take advantage of the cut in valuation and a more mature company. As a result, I altered the way I manage my speculative biotech investments and have enjoyed the benefits since. I was forced to watch FATE climb above $100 per share as the market began to realize Fate's potential. Sadly, my speculative investment strategy was not as sophisticated as Fate's platform technology and I exited the position before FATE peaked in early 2021. FATE was one of my favorite biotech investments back in 2017 and became one of my best trades over the next couple of years moving from $4 to over $40 per share.

For me, Fate Therapeutics ( NASDAQ: FATE ) is one of those companies thanks to its revolutionary induced pluripotent stem cell 'iPSC' technology.

#FATE THERAPEUTICS STOCK UPDATE#

Some of my favorite biotech companies are the ones that are pushing the edge of science far enough that they are going to force publishing companies to update their biology textbooks.

Fate therapeutics stock